UPL and FMC Corp collaborate on the active ingredient Rynaxypyr

The long-term strategic collaboration allows UPL to access key markets before the patent expires, in order to commercialize FMC Corporation’s main insecticide, Rynaxypyr active. Pursuant to the agreement, UPL will manufacture and contract Rynaxypyr to FMC in India, and FMC will supply the active ingredient to UPL on a market …

Read More »

Gyroscope Therapeutics Announces $ 148 Million Series C Funding

LONDON–(COMMERCIAL THREAD) – Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on the treatment of eye disease, today announced that it has raised US $ 148.0 million (£ 107.8 million) in as part of a Series C financing. The financing was led by Forbion’s Growth Opportunities Fund and includes …

Read More »